Application and latest research progress of HGF/c-MET inhibitors in advanced gastric cancer
10.3781/j.issn.1000-7431.2024.2308-0435
- VernacularTitle:HGF/c-MET抑制剂在晚期胃癌中的应用和最新研究进展
- Author:
Jiaqi SHI
1
,
2
,
3
;
Yang XU
;
Peipei GUO
;
Bin LI
;
Lixia LU
;
Ying ZHENG
;
Chuyi LI
;
Xiaohui YU
;
Jiayu CHEN
Author Information
1. 甘肃中医药大学中西医结合学院,甘肃 兰州 730000
2. 中国人民解放军联勤保障部队第九四〇医院消化内科,甘肃 兰州 730050
3. 中国人民解放军联勤保障部队第九四〇医院基础医学实验室,甘肃省干细胞与基因药物重点实验室,甘肃 兰州 730050
- Keywords:
Gastric cancer;
Advanced gastric cancer;
HGF/c-MET inhibitor;
Molecular Targeted therapy
- From:
Tumor
2024;44(2):201-214
- CountryChina
- Language:Chinese
-
Abstract:
Advanced gastric cancer(AGC)includes locally unresectable gastric cancer(GC),metastatic GC,and postoperative recurrent GC.Due to delayed diagnosis and lack of effective treatment for AGC,the median survival time of AGC patients is only 6-12 months.At present,the main treatment goal of AGC is to improve symptoms and prolong the survival time of patients receiving sequential chemotherapy.Although the therapeutic effect of systemic therapy on AGC is gradually becoming apparent,the patient's prognosis is far from expected.In addition,targeted therapy and novel immunotherapy have drawbacks such as high incidence of drug resistance,high toxic side effects,and heavy economic burden on patients.Therefore,finding new therapeutic targets and developing anti-tumor drugs is a key issue that urgently needs to be addressed.According to reports,abnormal activation of the hepatocyte growth factor(HGF)/cellular-mesenchymal epithelial transition factor(c-MET)pathway plays a crucial role in the progression of GC and the occurrence of multi-line resistance and may be a potential therapeutic target for GC.In recent years,some HGF/c-MET-targeting small molecule tyrosine kinase inhibitors(TKIs)have been found to show good clinical effects in the treatment of GC.Meanwhile,new HGF/c-MET inhibitors(such as monoclonal antibodies,bispecific antibodies,antibody drug conjugates,etc.)have shown good anti-tumor activity in preclinical studies,but they are all at different stages of clinical research,and their efficacy and safety still need further confirmation.This review elaborates on the latest research progress of HGF/c-MET inhibitors in the treatment of AGC and discusses the main reasons and strategies for drug resistance,aiming to provide better guidance for the treatment of AGC and provide reference for future research.
